A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

Study Purpose

This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

Inclusion Criteria for Part 1. 1. Male or female subjects must be at least at ≥18 and ≤75 years of age. 2. Subject has at least a three-month history of Ulcerative Colitis diagnosis at baseline. 3. Subject has active Ulcerative Colitis with a 9-point modified Mayo score of ≥ 5 at baseline, with an endoscopic subscore of ≥ 2. 4. Subject is deemed by the physician as having inadequate response, loss of response or intolerance to at least one conventional treatment (oral 5-ASA, immunosuppressants or corticosteroids), or was previously exposed to anti-TNF therapy (e.g., infliximab, adalimumab) or other biological treatment (e.g., vedolizumab) having. Discontinued the treatment for:
  • - Infliximab: a minimum of 8 weeks prior to baseline.
  • - Adalimumab: a minimum of 10 weeks prior to baseline.
  • - Ustekinumab: a minimum of 14 weeks prior to baseline.
  • - Vedolizumab: a minimum of 17 weeks prior to baseline.
Inclusion Criteria for Part 2 1. Subject has completed Part 1 and achieved clinical response at week 8. Inclusion Criteria for Part 3. 1. Subject has completed the 8-week Part 1 and was classified as not meeting clinical response criteria. OR Subject has discontinued treatment early in the Maintenance phase due to disease worsening OR Subject has completed the Maintenance phase. Study Exclusion Criteria for Part 1.

Exclusion Criteria:

1. Subject has a diagnosis of indeterminate colitis, or clinical findings suggestive of Crohn'sDisease. 2. Subject with Ulcerative Colitis, which is confined to a proctitis (distal 15 cm or less). 3. Treatment naïve subject diagnosed with Ulcerative Colitis (without previous exposure to any of the following therapies for UC treatment: oral 5-ASA, corticosteroids, immunosuppressants, or biological treatments). 4. Subject is displaying clinical signs of ischemic colitis, fulminant colitis or toxic megacolon. 5. Subject had previous surgery as a treatment for Ulcerative Colitis or likely to require surgery during the study period. 6. Subject has evidence of pathogenic bowel infection. Subjects had Clostridium difficile or other intestinal infection within 30 days of screening endoscopy or test positive at screening for C.difficile toxin or other intestinal pathogens. 7. Subject currently has or has a history of active tuberculosis (TB) or latent TB infection. 8. Subject is receiving any of the following therapies:
  • - Azathioprine/6-mercaptopurine, methotrexate, thalidomide within 7 days prior to baseline.
  • - Cyclosporine, mycophenolate, tacrolimus within 4 weeks prior to baseline.
  • - Interferon therapy within 8 weeks prior to baseline.
  • - Intravenous corticosteroids or rectally administered formulation of corticosteroids or 5- ASA within 2 weeks prior to baseline.
9. Subject had any prior treatment with lymphocyte-depleting agents/therapies (such as CamPath® [alemtuzumab], alkylating agents [e.g., cyclophosphamide or chlorambucil], total lymphoid irradiation, etc.). Subjects who have received rituximab or other selective B lymphocyte depleting agents are eligible if they have not received such therapy for at least 1 year prior to baseline. 10. Subject has previously received JAK inhibitors, such as tofacitinib, baricitinib, upadacitinib, filgotinib. 11. Subject with evidence of clinically relevant laboratory abnormalities which may affect subject safety or interpretation of study results at screening. 12. Subject has a screening 12-lead ECG that demonstrates clinically relevant abnormalities. 13. Subject currently has or had:
  • - A clinically significant infection within 1 month of baseline (e.g., those requiring hospitalization or parenteral antimicrobial therapy or have opportunistic infections).
  • - A history of more than one episode of herpes zoster, or disseminated zoster (single episode).
  • - Any infection otherwise judged by the investigator to have the potential for exacerbation by participation in the study.
  • - Any infection requiring antimicrobial therapy within 2 weeks of screening.
14. Subject has current immunization with any live virus vaccine or history of immunization with any live virus vaccine within 8 weeks of baseline. 15. Subject with a first-degree relative with a hereditary immunodeficiency. 16. Subject with a history of any lymphoproliferative disorder (such as EBV-related lymphoproliferative disorder, as reported in some subjects on other immunosuppressive drugs), history of lymphoma, leukemia, multiple myeloma, or signs and symptoms that are suggestive of current lymphatic disease. 17. Subject has any condition possibly affecting oral drug absorption e.g., gastrectomy, or clinically significant diabetic gastroenteropathy, or certain types of bariatric surgery such as gastric bypass. (Procedures such as gastric banding, gastric balloon that simply divide stomach into separate chambers, are NOT exclusionary.) Subject has undergone significant trauma or major surgery within 4 weeks of baseline. 18. Women who are pregnant or lactating, or planning pregnancy while enrolled in the study. Male who plan to donate sperm during the study and within 30 days after the last dose of study drug. 19. Subject who has a history of alcohol or drug abuse with less than 6 months of abstinence prior to baseline that in the opinion of the investigator will preclude participation in the study. 20. Subject with malignancies or with a history of malignancies with exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin. 21. Subject infected with human immunodeficiency virus (HIV) or hepatitis B or C viruses. 22. Subject has received any investigational drug or device within 3 months, or 5 half-lives (if known) prior to baseline. 23. Subject is receiving or expected to receive prohibited concomitant medication(s) in the 4 weeks prior to the first dose of study drug and through follow-up visit. 24. Any other condition which in the opinion of the investigator would make the subject unsuitable for inclusion in the study. 25. Subject with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease), or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study. 26. Subject with a history of thromboembolic events, including deep vein thromboses (DVT), pulmonary embolism (PE), and those with known inherited conditions that predispose to hypercoagulability. Study Exclusion Criteria for Parts 2 and 3. 1. Subject with any clinically significant condition at the end of 8-week Induction treatment from Part 1 Induction phase, and Part 2 Maintenance Phase that in the opinion of investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis. 2. Subject who, in the opinion of the investigator or sponsor, is unlikely to be cooperative or able to comply with study procedures, or any other condition which in the opinion of the investigator would make the subject unsuitable for inclusion.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05181137
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Reistone Biopharma Company Limited
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries China, Georgia, Poland, Ukraine, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Ulcerative Colitis
Additional Details

This study consists of a screening period followed by a placebo-controlled Part 1 phase and then a placebo-controlled Part 2 phase. An open label Part 3 phase is open to subjects who: complete the Part 2, are considered non-responders following the Part 1, or have disease worsening during Part 2.

Arms & Interventions

Arms

Experimental: Part 1 Active Experimental: SHR0302 Dose#1

SHR0302 Oral tablets taken once daily (QD) for 8 weeks SHR0302 Oral tablets taken once daily (QD)

Placebo Comparator: Part 1 Placebo Comparator: Placebo

Placebo Oral tablets taken once daily (QD) for 8 weeks

Experimental: Part 2 Active Experimental: SHR0302 Dose#2

SHR0302 Oral tablets taken once daily (QD) for 44 weeks

Placebo Comparator: Part 2 Placebo Comparator: Placebo

Placebo Comparator: Maintenance Treatment Placebo Comparator: Placebo

Experimental: Part 3 Active Experimental: SHR0302 Dose#2

SHR0302 Oral tablets taken once daily (QD) for 26 weeks

Interventions

Drug: - SHR0302

Oral tablets taken once daily (QD)

Drug: - Placebo

Oral tablets taken once daily (QD)

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Digestive Health Specialists, Dothan, Alabama

Status

Completed

Address

Digestive Health Specialists

Dothan, Alabama, 36301

Om Research LLC, Lancaster, California

Status

Terminated

Address

Om Research LLC

Lancaster, California, 93534

Yale University, New Haven, Connecticut

Status

Terminated

Address

Yale University

New Haven, Connecticut, 06510

IHS Health, Kissimmee, Florida

Status

Active, not recruiting

Address

IHS Health

Kissimmee, Florida, 34741

Dade Research Center, Miami, Florida

Status

Terminated

Address

Dade Research Center

Miami, Florida, 33126

Gastro Florida, Pinellas Park, Florida

Status

Completed

Address

Gastro Florida

Pinellas Park, Florida, 33781

One Health Research Clinic Atlanta, LLC, Norcross, Georgia

Status

Active, not recruiting

Address

One Health Research Clinic Atlanta, LLC

Norcross, Georgia, 30039

John Hopkins University, Columbia, Maryland

Status

Terminated

Address

John Hopkins University

Columbia, Maryland, 21045

Michigan Medical, Ann Arbor, Michigan

Status

Terminated

Address

Michigan Medical

Ann Arbor, Michigan, 48109

Research Institute of Michigan, Chesterfield, Michigan

Status

Withdrawn

Address

Research Institute of Michigan

Chesterfield, Michigan, 48047

NY Scientific, Brooklyn, New York

Status

Terminated

Address

NY Scientific

Brooklyn, New York, 11235

North Massapequa, New York

Status

Terminated

Address

DiGiovanna Institute for Medical Education & Research

North Massapequa, New York, 11758

Chapel Hill, North Carolina

Status

Terminated

Address

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599

Charlotte, North Carolina

Status

Withdrawn

Address

Charlotte Gastroenterology & Hepatology P.L.L.C

Charlotte, North Carolina, 28207

DDSI, Oklahoma City, Oklahoma

Status

Withdrawn

Address

DDSI

Oklahoma City, Oklahoma, 73112

Central Sooner Research, Oklahoma City, Oklahoma

Status

Terminated

Address

Central Sooner Research

Oklahoma City, Oklahoma, 73118

Vanderbilt University Medical Center, Nashville, Tennessee

Status

Terminated

Address

Vanderbilt University Medical Center

Nashville, Tennessee, 37204

Omni Clinical Research, Houston, Texas

Status

Terminated

Address

Omni Clinical Research

Houston, Texas, 77034

UTMB Health, League City, Texas

Status

Terminated

Address

UTMB Health

League City, Texas, 77573

University of Utah, Salt Lake City, Utah

Status

Terminated

Address

University of Utah

Salt Lake City, Utah, 84132

McGuire Research Institute, Richmond, Virginia

Status

Terminated

Address

McGuire Research Institute

Richmond, Virginia, 23249

IACT Health, Suffolk, Virginia

Status

Withdrawn

Address

IACT Health

Suffolk, Virginia, 23435

Milwaukee, Wisconsin

Status

Terminated

Address

Advocate Aurora Health - Aurora St. Luke's Medical Center

Milwaukee, Wisconsin, 53215

International Sites

Bengbu, Anhui, China

Status

Recruiting

Address

The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui,

Site Contact

Qizhi Wang

co.us@reistonebio.com

(647)9602308

Anhui Provincial Hospital, Hefei, Anhui, China

Status

Recruiting

Address

Anhui Provincial Hospital

Hefei, Anhui,

Site Contact

Li Xie

co.us@reistonebio.com

(647)9602308

Beijing, Beijing, China

Status

Recruiting

Address

Beijing Military Area General Hospital/Seventh Medical Center of PLA General Hospital

Beijing, Beijing,

Site Contact

Jianqiu Sheng

co.us@reistonebio.com

(647)9602308

Peking University First Hospital, Beijing, Beijing, China

Status

Terminated

Address

Peking University First Hospital

Beijing, Beijing,

Peking University Third Hospital, Beijing, Beijing, China

Status

Recruiting

Address

Peking University Third Hospital

Beijing, Beijing,

Site Contact

Shigang Ding

co.us@reistonebio.com

(647)9602308

Tsinghua University Changgung Hospital, Beijing, Beijing, China

Status

Active, not recruiting

Address

Tsinghua University Changgung Hospital

Beijing, Beijing,

Army Medical Center of PLA, Chongqing, Chongqing, China

Status

Not yet recruiting

Address

Army Medical Center of PLA

Chongqing, Chongqing,

Site Contact

Dongfeng Chen

co.us@reistonebio.com

(647)9602308

Chongqing People's Hospital, Chongqing, Chongqing, China

Status

Active, not recruiting

Address

Chongqing People's Hospital

Chongqing, Chongqing,

Chongqing, Chongqing, China

Status

Recruiting

Address

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing,

Site Contact

Bingqiang Zhang

co.us@reistonebio.com

(647)9602308

Fuzhou, Fujian, China

Status

Recruiting

Address

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian,

Site Contact

Chengdang Wang

co.us@reistonebio.com

(647)9602308

Xiamen, Fujian, China

Status

Not yet recruiting

Address

The First Affiliated Hospitial of Xiamen University

Xiamen, Fujian,

Site Contact

Jianwei Zheng

co.us@reistonebio.com

(647)9602308

Guangzhou First People's Hospital, Guangzhou, Guangdong, China

Status

Recruiting

Address

Guangzhou First People's Hospital

Guangzhou, Guangdong,

Site Contact

Yongjia Zhou

co.us@reistonebio.com

(647)9602308

Guangzhou, Guangdong, China

Status

Recruiting

Address

The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong,

Site Contact

Baili Chen

co.us@reistonebio.com

(647)9602308

Guangzhou, Guangdong, China

Status

Recruiting

Address

The Sixth Affiliated Hospital of Sun Yat-Sen University

Guangzhou, Guangdong,

Site Contact

Xiang Gao

co.us@reistonebio.com

(647)9602308

Guangzhou, Guangdong, China

Status

Active, not recruiting

Address

Third Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong,

Peking University Shenzhen Hospital, Shenzhen, Guangdong, China

Status

Recruiting

Address

Peking University Shenzhen Hospital

Shenzhen, Guangdong,

Site Contact

Bing Zou

co.us@reistonebio.com

(647)9602308

Nanning, Guangxi, China

Status

Recruiting

Address

The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi,

Site Contact

Xiaoping Lv

co.us@reistonebio.com

(647)9602308

Shijiazhuang, Hebei, China

Status

Recruiting

Address

The Second Hospital of Hebei Medical University

Shijiazhuang, Hebei,

Site Contact

Xiaolan Zhang

co.us@reistonebio.com

(647)9602308

Luoyang, Henan, China

Status

Recruiting

Address

The First Affiliated Hospital of Henan University of Science and Technoloy

Luoyang, Henan,

Site Contact

Yingjian Zhang

co.us@reistonebio.com

(647)9602308

Henan Provincial People's Hospital, Zhengzhou, Henan, China

Status

Recruiting

Address

Henan Provincial People's Hospital

Zhengzhou, Henan,

Site Contact

Xiuling Li

co.us@reistonebio.com

(647)9602308

Zhengzhou, Henan, China

Status

Recruiting

Address

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan,

Site Contact

Bingrong Liu

co.us@reistonebio.com

(647)9602308

Zhengzhou, Hena, China

Status

Recruiting

Address

The Second Affiliated Hospital of Zhengzhou University

Zhengzhou, Hena,

Site Contact

Baisui Feng

co.us@reistonebio.com

(647)9602308

Jingzhou First People's Hospital, Jingzhou, Hubei, China

Status

Active, not recruiting

Address

Jingzhou First People's Hospital

Jingzhou, Hubei,

Shiyan, Hubei, China

Status

Recruiting

Address

Affiliated Taihe Hospital of Hubei University of Medicine

Shiyan, Hubei,

Renmin Hospital of Wuhan University, Wuhan, Hubei, China

Status

Not yet recruiting

Address

Renmin Hospital of Wuhan University

Wuhan, Hubei,

Site Contact

Ping An

co.us@reistonebio.com

(647)9602308

Changsha, Hunan, China

Status

Recruiting

Address

The Second Xiangya Hospital of Central South University

Changsha, Hunan,

Site Contact

Xuehong Wang

co.us@reistonebio.com

(647)9602308

Changsha, Hunan, China

Status

Recruiting

Address

Xiangya Hospital Central South University

Changsha, Hunan,

Site Contact

Xiaomei Zhang

co.us@reistonebio.com

(647)9602308

Zhuzhou Central Hospital, Zhuzhou, Hunan, China

Status

Not yet recruiting

Address

Zhuzhou Central Hospital

Zhuzhou, Hunan,

Site Contact

Hongbing Zhou

co.us@reistonebio.com

(647)9602308

Baotou Central Hospital, Baotou, Inner Mongolia, China

Status

Recruiting

Address

Baotou Central Hospital

Baotou, Inner Mongolia,

Site Contact

Ling Zhang

co.us@reistonebio.com

(647)9602308

Huai'an First People's Hospital, Huai'an, Jiangsu, China

Status

Recruiting

Address

Huai'an First People's Hospital

Huai'an, Jiangsu,

Site Contact

Weijie Dai

co.us@reistonebio.com

(647)9602308

Jiangsu Province Hospital, Nanjing, Jiangsu, China

Status

Not yet recruiting

Address

Jiangsu Province Hospital

Nanjing, Jiangsu,

Site Contact

Hongjie Zhang

co.us@reistonebio.com

(647)9602308

Nanjing First Hospital, Nanjing, Jiangsu, China

Status

Recruiting

Address

Nanjing First Hospital

Nanjing, Jiangsu,

Site Contact

Zhenyu Zhang

co.us@reistonebio.com

(647)9602308

Nanjing, Jiangsu, China

Status

Recruiting

Address

Nanjing General Hospital of Nanjing Military Command

Nanjing, Jiangsu,

Site Contact

Fangyu Wang

co.us@reistonebio.com

(647)9602308

Zhongda Hospital Southeast University, Nanjing, Jiangsu, China

Status

Recruiting

Address

Zhongda Hospital Southeast University

Nanjing, Jiangsu,

Site Contact

Hong Chen

co.us@reistonebio.com

(647)9602308

Suzhou, Jiangsu, China

Status

Recruiting

Address

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu,

Site Contact

Weichang Chen

co.us@reistonebio.com

(647)9602308

Yangzhou, Jiangsu, China

Status

Recruiting

Address

Subei People's Hospital of Jiangsu province

Yangzhou, Jiangsu,

Site Contact

Zhen Zhu

co.us@reistonebio.com

(647)9602308

Shenyang, Liaoning, China

Status

Recruiting

Address

Shengjing Hospital Of China Medical University

Shenyang, Liaoning,

Site Contact

Changqing Zheng

co.us@reistonebio.com

(647)9602308

Shenyang, Liaoning, China

Status

Terminated

Address

The First Hospital of China Medical University

Shenyang, Liaoning,

Liaocheng People's Hospital, Liaocheng, Shandong, China

Status

Recruiting

Address

Liaocheng People's Hospital

Liaocheng, Shandong,

Site Contact

Peng Yan

co.us@reistonebio.com

(647)9602308

Binzhou Medical University Hospital, Binzhou, Shandon, China

Status

Recruiting

Address

Binzhou Medical University Hospital

Binzhou, Shandon,

Huashan Hospital, Fudan University, Shanghai, Shanghai, China

Status

Recruiting

Address

Huashan Hospital, Fudan University

Shanghai, Shanghai,

Site Contact

Liang Zhong

co.us@reistonebio.com

(647)9602308

Shanghai, Shanghai, China

Status

Recruiting

Address

Longhua Hospital Shanghai University of Traditional Chinese Medicine

Shanghai, Shanghai,

Site Contact

Jiang Lin

co.us@reistonebio.com

(647)9602308

Shanghai, Shanghai, China

Status

Terminated

Address

Renji Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai,

Shanghai, Shanghai, China

Status

Recruiting

Address

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai,

Site Contact

Jie Zhong

co.us@reistonebio.com

(647)9602308

Shanghai Changhai Hospital, Shanghai, Shanghai, China

Status

Recruiting

Address

Shanghai Changhai Hospital

Shanghai, Shanghai,

Site Contact

Yiqi Du

co.us@reistonebio.com

(647)9602308

Shanghai East Hospital, Shanghai, Shanghai, China

Status

Recruiting

Address

Shanghai East Hospital

Shanghai, Shanghai,

Site Contact

Fei Liu

co.us@reistonebio.com

(647)9602308

Shanghai General Hospital, Shanghai, Shanghai, China

Status

Not yet recruiting

Address

Shanghai General Hospital

Shanghai, Shanghai,

Site Contact

Lungen Lu

co.us@reistonebio.com

(647)9602308

Shanghai Sixth People's Hospital, Shanghai, Shanghai, China

Status

Terminated

Address

Shanghai Sixth People's Hospital

Shanghai, Shanghai,

Shanghai, Shanghai, China

Status

Recruiting

Address

Zhongshan Hospital Affiliated to Fudan University

Shanghai, Shanghai,

Site Contact

Xizhong Shen

co.us@reistonebio.com

(647)9602308

Shanxi Provincial People's Hospital, Shanxi, Shanxi, China

Status

Terminated

Address

Shanxi Provincial People's Hospital

Shanxi, Shanxi,

Taiyuan, Shanxi, China

Status

Recruiting

Address

The First Hospital of Shanxi Medical University

Taiyuan, Shanxi,

Site Contact

Lijuan Huo

co.us@reistonebio.com

(647)9602308

West China Hospital Sichuan University, Chengdu, Sichuan, China

Status

Recruiting

Address

West China Hospital Sichuan University

Chengdu, Sichuan,

Site Contact

Yan Zhang

co.us@reistonebio.com

(647)9602308

Tianjin, Tianjin, China

Status

Recruiting

Address

Tianjin medical University General Hospital

Tianjin, Tianjin,

Site Contact

Bangmao Wang

co.us@reistonebio.com

(647)9602308

Tianjin Union Medical Center, Tianjin, Tianjin, China

Status

Recruiting

Address

Tianjin Union Medical Center

Tianjin, Tianjin,

Site Contact

Yandi Liu

co.us@reistonebio.com

(647)9602308

Hangzhou, Zhejiang, China

Status

Recruiting

Address

The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine

Hangzhou, Zhejiang,

Site Contact

Yihong Fan

co.us@reistonebio.com

(647)9602308

Hangzhou, Zhejiang, China

Status

Recruiting

Address

The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang,

Site Contact

Yan Chen

co.us@reistonebio.com

(647)9602308

Jinhua Municipal Central Hospical, Jinhua, Zhejiang, China

Status

Not yet recruiting

Address

Jinhua Municipal Central Hospical

Jinhua, Zhejiang,

Site Contact

Jin Ding

co.us@reistonebio.com

(647)9602308

Ningbo First Hospital, Ningbo, Zhejiang, China

Status

Recruiting

Address

Ningbo First Hospital

Ningbo, Zhejiang,

Site Contact

Xiaoyun Ding

co.us@reistonebio.com

(647)9602308

Wenzhou, Zhejiang, China

Status

Recruiting

Address

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang,

Site Contact

Xiangrong Chen

co.us@reistonebio.com

(647)9602308

Curatio, Jsc, Tbilisi, Georgia

Status

Active, not recruiting

Address

Curatio, Jsc

Tbilisi, ,

Tbilisi, Georgia

Status

Active, not recruiting

Address

JSC Infectious Diseases, AIDS and Clinical Immunology Research Center

Tbilisi, ,

Tbilisi, Georgia

Status

Active, not recruiting

Address

LTD Central University Clinic After Academic N. Kipshidze

Tbilisi, ,

LTD The First Medical Center, Tbilisi, Georgia

Status

Active, not recruiting

Address

LTD The First Medical Center

Tbilisi, ,

Bydgoszcz, Poland

Status

Withdrawn

Address

CLINSANTE Clinical Research Centre Ewa Galczak-Nowak, Malgorzata Trzaska

Bydgoszcz, ,

Knurow, Poland

Status

Active, not recruiting

Address

MZ BADANIA Slowik Zymla General Partnership

Knurow, ,

"Landa" Specialist Doctor's Offices, Krakow, Poland

Status

Withdrawn

Address

"Landa" Specialist Doctor's Offices

Krakow, ,

PLEJADY Medical Centre, Krakow, Poland

Status

Active, not recruiting

Address

PLEJADY Medical Centre

Krakow, ,

AMED Medical Centre Branch in Lodz, Lodz, Poland

Status

Withdrawn

Address

AMED Medical Centre Branch in Lodz

Lodz, ,

Oswiecim Clinical Trial Centre, Oswiecim, Poland

Status

Active, not recruiting

Address

Oswiecim Clinical Trial Centre

Oswiecim, ,

Poznan, Poland

Status

Withdrawn

Address

Private Healthcare Institution Specialist Clinics Termedica

Poznan, ,

Sopot, Poland

Status

Active, not recruiting

Address

Dariusz Kleczkowski Specialist Medical Practice

Sopot, ,

Torun Gastrology Centre "Gastromed", Torun, Poland

Status

Active, not recruiting

Address

Torun Gastrology Centre "Gastromed"

Torun, ,

MDM Healthcare Centre, Warsaw, Poland

Status

Withdrawn

Address

MDM Healthcare Centre

Warsaw, ,

WIP Warsaw IBD Point, Warsaw, Poland

Status

Active, not recruiting

Address

WIP Warsaw IBD Point

Warsaw, ,

Medical Centre Oporow, Wroclaw, Poland

Status

Active, not recruiting

Address

Medical Centre Oporow

Wroclaw, ,

ETG Zamosc, Zamosc, Poland

Status

Active, not recruiting

Address

ETG Zamosc

Zamosc, ,

Cherkasy, Ukraine

Status

Active, not recruiting

Address

Communal Nonprofit Enterprise "Cherkasy Regional Hospital of Cherkasy Oblast Council"

Cherkasy, ,

Chernivtsi, Ukraine

Status

Withdrawn

Address

Regional Municipal Non-commercial Enterprise "Chernivtsi Emergency Medical Hospital"

Chernivtsi, ,

Ivano-Frankivsk, Ukraine

Status

Withdrawn

Address

Public Non-Profit Enterprise "Regional Clinical Hospital under Ivano-Frankivsk Regional Council"

Ivano-Frankivsk, ,

Kharkiv, Ukraine

Status

Withdrawn

Address

Public Non-Profit Institution: O.O. Shalimov City Clinical Hospital #2 under Kharkiv City Council

Kharkiv, ,

Khmelnytskyi, Ukraine

Status

Withdrawn

Address

Public Non-Profit Enterprise "Khmelnytskyi Regional Hospital" under Khmelnytskyi Regional Council

Khmelnytskyi, ,

Clinical Hospital "Feofaniia", Kyiv, Ukraine

Status

Active, not recruiting

Address

Clinical Hospital "Feofaniia"

Kyiv, ,

Medical Center "Consylium Medical", Kyiv, Ukraine

Status

Active, not recruiting

Address

Medical Center "Consylium Medical"

Kyiv, ,

Kyiv, Ukraine

Status

Withdrawn

Address

Medical Center OK!Clinic+ of the Company with Limited Liability International Institute of Clinical Research

Kyiv, ,

Lutsk, Ukraine

Status

Active, not recruiting

Address

Municipal Enterprise "Volyn Regional Clinical Hospital" of Volyn Regional Council

Lutsk, ,

Lviv, Ukraine

Status

Withdrawn

Address

Communal Noncommercial Enterprise of Lviv Regional Council "Lviv Regional Clinical Hospital"

Lviv, ,

Sumy, Ukraine

Status

Withdrawn

Address

Public Non-Profit Enterprise under Sumy Regional Council "Sumy Regional Clinical Hospital"

Sumy, ,

Vinnytsia, Ukraine

Status

Withdrawn

Address

Communal Non-Commercial Enterprise: Vinnytsia City Clinical Hospital #1

Vinnytsia, ,

Zaporizhia, Ukraine

Status

Active, not recruiting

Address

Public Non-Profit Enterprise "City Hospital #6" under Zaporizhia City Council

Zaporizhia, ,

"Medibor Plus" Llc, Zhytomyr, Ukraine

Status

Active, not recruiting

Address

"Medibor Plus" Llc

Zhytomyr, ,

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation. For a full description of terms please refer to our Terms, Conditions & Privacy.